August 31, 2016 12:46 AM ET

Biotechnology

Company Overview of Oryzon Genomics S.A.

Company Overview

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies to treat oncology and neurodegenerative diseases. Its clinical-stage product candidates include ORY-1001, an oncology product, which is in Phase I/IIA clinical trial for treating acute leukemia disease; and ORY-2001, a dual selective LSD1 and MAO-B inhibitor that is in Phase I clinical trial for Alzheimer and other diseases. The company has collaboration agreement with ROCHE for the development of its product, ORY-1001. Oryzon Genomics S.A. was founded in 2000 and is headquartered in Barcelona, Spain.

Sant Ferran 74

Cornella de Llobregat

Barcelona,  08940

Spain

Founded in 2000

33.8 Employees

Phone:

34 93 515 13 13

Fax:

34 93 377 40 28

Key Executives for Oryzon Genomics S.A.

Co-Founder, Chairman and Chief Executive Officer
Total Annual Compensation: €148.2K
First Deputy President and Chief Scientific Officer
Total Annual Compensation: €148.2K
Compensation as of Fiscal Year 2014.

Oryzon Genomics S.A. Key Developments

Oryzon Genomics Announces Earnings Results for the First Half Ended June 30, 2016

Oryzon Genomics announced earnings results for the first half ended June 30, 2016. For the first half, the company reported net loss was $3.1 million ($0.1 per share) compared to a net loss $0.03 million ($0.001 per share) a year ago.

Oryzon Genomics Designates ORY- 3001, for Preclinical Development

Oryzon Genomics announced that it has designated its next drug, ORY-3001, for preclinical development. This is the third drug candidate produced by the company, a first-in-class specific Lysine Specific Demethylase 1 (LSD1) inhibitor for the treatment of, yet undisclosed, non-oncological conditions. LSD1 is an enzyme that removes methyl marks from lysine 4 of histone H3, a nucleosomal protein involved in the organization and control of accessibility of DNA for transcription.

Oryzon Genomics S.A., Annual General Meeting, Jun 29, 2016

Oryzon Genomics S.A., Annual General Meeting, Jun 29, 2016. Location: San Fernando, 74, Cornellà de Llobregat Barcelona Spain

Similar Private Companies By Industry

Company Name Region
A.S.A.C. Pharmaceutical I.A.E. Europe
ABAC Therapeutics SA Europe
Advanced In Vitro Cell Technologies S.A. Europe
Advanced Marker Discovery, S.L. Europe
Agrasys S.L. Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Oryzon Genomics S.A., please visit www.oryzon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.